Omalizumab Antibody | AbD20760_hIgG1

//www.bio-rad-antibodies.com/omalizumab-antibody-abd20760-higg1-hca237.html?RenderPageSpecific=1
Omalizumab Antibody | AbD20760_hIgG1 gallery image 1

Human anti omalizumab specificity ELISA

A microtiter plate was coated over night with various antigens at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti omalizumab (clone AbD20760_hIgG1) at a concentration of 2 µg/ml followed by QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
Omalizumab Antibody | AbD20760_hIgG1 gallery image 2

Human anti omalizumab specificity titration ELISA

A microtiter plate was coated over night with various antigens. For IgE/drug complex antigen, human IgE (HCA171) was immobilized to the plate. After washing and blocking, omalizumab was added. After further incubation and washing steps, detection was performed using HRP-conjugated Human anti omalizumab (clone AbD20760_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
Omalizumab Antibody | AbD20760_hIgG1 gallery image 3

Omalizumab antigen-capture ELISA for PK assay development

A microtiter plate was coated over night with human IgE (HCA171) at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of omalizumab. Detection was performed using HRP-conjugated Human anti omalizumab (clone AbD20760_hIgG1) at a concentration of 2 µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
  • Omalizumab Antibody | AbD20760_hIgG1 thumbnail image 1
  • Omalizumab Antibody | AbD20760_hIgG1 thumbnail image 2
  • Omalizumab Antibody | AbD20760_hIgG1 thumbnail image 3
  • Human anti Omalizumab (Drug/Target Complex)
  • Human anti Omalizumab (Drug/Target Complex):HRP
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-omalizumab drug-target complex antibody specifically recognizes the omalizumab-hIgE complex exclusively and detects omalizumab or biosimilars only when bound to human IgE. This antibody is in full IgG1 format and is suitable for a PK antigen capture format assay to detect bound drug.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD20760_hIgG1
    • Isotype
      IgG1
    2 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA237Edatasheet pdfdatasheet pdf0.1 mg
      HCA237
      HCA237PEdatasheet pdfdatasheet pdf0.1 mg
      HCA237P
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti omalizumab, clone AbD20760_hIgG1 binds specifically to the omalizumab/IgE (drug/target) complex. The antibody does not recognize free omalizumab or free human IgE. It can be used in bioanalytical assays to detect bound omalizumab or biosimilar products exclusively.

        Clone AbD20760_hIgG1 can be used to develop a pharmacokinetic (PK) antigen capture assay to measure omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in preclinical or clinical samples. This product is in a full immunoglobulin format and is available directly labeled with HRP. The antibody is also available in unlabeled Fab format (HCA238).

        Omalizumab (brand name Xolair®) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

        Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.

        View a summary of all anti-omalizumab antibodies
      • Intended Use
      • Product Form
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line.This antibody is supplied as a liquid.
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
      • Reconstitution
      • Preparation
        Purified IgG prepared by affinity chromatography on Protein A
        Purified IgG prepared by affinity chromatography on Protein A
      • Preservative Stabilisers
        0.01% Thiomersal
        0.01% Thiomersal
      • Immunogen
        Omalizumab
      • Purity
      • Affinity
        The monovalent intrinsic affinity of this antibody was measured as KD = 0.58 nM by real time, label free molecular interaction analysis on immobilized omalizumab in complex with human IgE.
      • Approx. Protein Concentrations
        IgG concentration 0.5 mg/ml
        IgG concentration 0.1 mg/ml
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline
        Phosphate buffered saline
      • Storage
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
        Store at -70oC.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
      • Shelf Life
        12 months from date of despatch
        12 months from date of despatch
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Xolair® is a registered trademark of Novartis.
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Xolair® is a registered trademark of Novartis.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA
      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • Recommended Protocol
      • ELISA
        This product may be used in a direct ELISA to detect the omalizumab/IgE complex or to detect omalizumab bound to immobilized IgE.
        Protocol: PK antigen capture ELISA to measure bound drug exclusively
      • ELISA
        This product may be used in a direct ELISA to detect the omalizumab/IgE complex or to detect omalizumab bound to immobilized IgE.
        Protocol: PK antigen capture ELISA to measure bound drug exclusively
      • Immunohistology
      • Immunohistology
      • Histology Positive Control Tissue
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Immunofluorescence
      • Western Blotting
      • Western Blotting
      • Instructions For Use
      • Instructions For Use

      Additional Omalizumab Antibody Formats

      Formats Clone Applications Sizes available
      Omalizumab Antibody : Purified AbD20760_hIgG1 E 0.1 mg
      Omalizumab Antibody : HRP AbD20760_hIgG1 E 0.1 mg
      • Copyright © 2016 Bio-Rad

      Recommended Secondary Antibody

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            LYNX Rapid HRP Antibody Conjugation KitLNK002P3 Conjugations For 400µg AntibodyCJ
            LNK002P
            Recombinant Human IgE LambdaHCA1710.1 mgE
            HCA171
            Recombinant Human IgE KappaHCA1900.1 mgE
            HCA190
            Human anti OmalizumabHCA2350.1 mgE
            HCA235
            Human anti OmalizumabHCA2360.1 mgE
            HCA236
            Human anti Omalizumab (Drug/Target Complex)HCA2380.1 mgE
            HCA238
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A
            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            Recombinant Human IgE LambdaHCA1710.1 mgE
            HCA171
            Recombinant Human IgE KappaHCA1900.1 mgE
            HCA190
            Human anti OmalizumabHCA2350.1 mgE
            HCA235
            Human anti OmalizumabHCA2360.1 mgE
            HCA236
            Human anti Omalizumab (Drug/Target Complex)HCA2380.1 mgE
            HCA238
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A

            Recommended Positive Controls

              Histology Controls

                Write your review

                You may also be interested in...